卡铂
医学
化疗
腺样囊性癌
病态的
紫杉醇
涎腺癌
内科学
唾液腺
肿瘤科
涎腺导管癌
癌症
癌
胃肠病学
顺铂
作者
Kenji Nakano,Yukiko Sato,Takeshi Sasaki,Wataru Shimbashi,Hirofumi Fukushima,Hiroyuki Yonekawa,Hiroki Mitani,Kazuyoshi Kawabata,Shunji Takahashi
标识
DOI:10.3109/00016489.2016.1170876
摘要
A standard chemotherapy for recurrent/metastatic salivary gland cancers has not been established. Combination chemotherapy of carboplatin and paclitaxel should be evaluated as a treatment option.This study retrospectively reviewed salivary gland cancer patients who received combination chemotherapy of carboplatin and paclitaxel. The differences in objective responses and in the prognoses according to the different pathological diagnoses were evaluated.A total of 38 patients were enrolled in the study; of them, 18 had salivary duct carcinomas (SDCs), nine had adenoid cystic carcinomas (ACCs), and 11 had other pathological diagnoses. Objective responses were observed in 15 (39%) patients. The median progression-free survival (PFS) was 6.5 months, and the median overall survival (OS) was 26.5 months. ACC patients had relatively low response rates (9%), but there were no significant differences in PFS or OS compared to other sub-types. The treatment was well tolerated, with few adverse events.Salivary gland cancer patients showed a moderate clinical response to the combination chemotherapy of carboplatin and paclitaxel. The objective response rates differed according to the pathological diagnoses, but there were no significant differences in prognoses.
科研通智能强力驱动
Strongly Powered by AbleSci AI